Hall Susan A, Kupelian Varant, Rosen Raymond C, Travison Thomas G, Link Carol L, Miner Martin M, Ganz Peter, McKinlay John B
Department of Epidemiology, New England Research Institutes, Watertown, MA 02472, USA.
J Sex Med. 2009 May;6(5):1402-13. doi: 10.1111/j.1743-6109.2008.01207.x. Epub 2009 Feb 9.
Studies and reports suggest that both hyperlipidemia and its pharmacologic treatment may lead to an increased risk of erectile dysfunction (ED).
Our objectives were to examine the association between (i) treated hyperlipidemia and ED; and (ii) untreated hyperlipidemia and ED.
Data from 1,899 men aged 30-79 were used from the Boston Area Community Health Survey of community-dwelling residents of Boston, MA, collected during 2002-2005 using an in-person interview, self-administered questionnaires, and a venous blood draw.
ED was measured using the short form International Index of Erectile Function. A case of treated hyperlipidemia was defined by use of anti-lipemics in the past month, while untreated hyperlipidemia was serum total cholesterol > or =240 milligrams per deciliter with no anti-lipemic use. We estimated associations using odds ratios (ORs) and 95% confidence intervals (CIs) from multivariate logistic regression.
Men with treated hyperlipidemia were older, had more comorbidities, and used more medications compared with men with untreated hyperlipidemia or no hyperlipidemia. In multivariate models stratified by age and the presence of diabetes and/or cardiovascular disease (CVD), we saw no association between hyperlipidemia drug treatment and ED, except among younger men (<55) who had diabetes and/or CVD, where a strong association with an imprecise CI was observed (OR = 10.39, 95% CI: 3.25, 33.20). There was no significant positive association between untreated hyperlipidemia and ED in any multivariate model.
Lipid-lowering medications may be associated with ED among some men. The well-established benefits of lipid-lowering therapy should always be weighed against potential adverse effects.
研究和报告表明，高脂血症及其药物治疗均可能导致勃起功能障碍（ED）风险增加。
我们的目标是研究（i）接受治疗的高脂血症与ED之间的关联；以及（ii）未经治疗的高脂血症与ED之间的关联。
使用来自马萨诸塞州波士顿社区居民的波士顿地区社区健康调查中的1899名30 - 79岁男性的数据，这些数据于2002 - 2005年通过面对面访谈、自行填写问卷和静脉采血收集。
使用勃起功能国际指数简表测量ED。过去一个月内使用抗血脂药物定义为接受治疗的高脂血症病例，而未经治疗的高脂血症定义为血清总胆固醇≥240毫克/分升且未使用抗血脂药物。我们使用多变量逻辑回归的比值比（OR）和95%置信区间（CI）估计关联。
与未经治疗的高脂血症或无高脂血症的男性相比，接受治疗的高脂血症男性年龄更大，合并症更多，使用的药物更多。在按年龄以及糖尿病和/或心血管疾病（CVD）的存在进行分层的多变量模型中，我们未发现高脂血症药物治疗与ED之间存在关联，但在患有糖尿病和/或CVD的年轻男性（<55岁）中观察到强关联且CI不精确（OR = 10.39，95% CI：3.25，33.20）。在任何多变量模型中，未经治疗的高脂血症与ED之间均无显著正相关。
降脂药物可能与部分男性的ED有关。降脂治疗的既定益处应始终与潜在的不良反应相权衡。
